Skip to content

The establishment and evaluation of the B7H3 immunohistochemical automatic evaluation system based on deep learning for the glioblastoma microvascular construction

The establishment and evaluation of the B7H3 immunohistochemical automatic evaluation system based on deep learning for the glioblastoma microvascular construction

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036695
Enrollment
Unknown
Registered
2020-08-24
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glioblastoma

Interventions

Gold Standard:B7H3 pathologist's interpretation
Index test:The&#32
artificial&#32
diagnosis&#32
system&#32
(automatically&#32
the&#32
composition&#32
and&#32
proportions&#32
of&#32
various&#32
components&#32
in&#32

Sponsors

Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Complete clinical data and pathological information; 2. Patients who signed written informed consent to participate in the study. 3. Sections of glioblastoma stained with B7H3 immunohistochemistry; 4. The number of tumor cells under microscope is more than 100.

Exclusion criteria

Exclusion criteria: 1. Preoperative treatment (neoadjuvant chemotherapy or radiotherapy); 2. Recurrent glioblastoma.

Design outcomes

Primary

MeasureTime frame
consistency;

Countries

China

Contacts

Public ContactHaibo Zhang

Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine

kexue168163@163.com+86 13788904795

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026